scPharmaceuticals’ (NSDQ:SCPH) has signed a development agreement to incorporate West Pharmaceutical Services’ (NYSE:WST) SmartDose drug delivery system with Furoscix, a drug that scPharmaceuticals developed to treat edema in heart failure patients.
Burlington, Mass.-based scPharmaceuticals recently completed preliminary feasibility studies of the drug-device combination. The testing included drug stability in the pre-filled cartridge, drug compatibility, and overall performance within Furoscix-delivery specifications. Previously FDA-approved SmartDose allows patients to self-administer medication in accordance with their prescribed treatment. It adheres to the patient’s body, enabling hands-free administration.
“We believe the features and functionality of the SmartDose system improve the overall patient experience with Furoscix,” saidscPharmaceuticals president and CEO John Tucker. “Heart failure remains a large market opportunity with high unmet patient need and significant associated healthcare costs. We anticipate filing a New Drug Application for FUROSCIX with the next-generation technology in 2020, subject to meeting with the Food and Drug Administration (FDA) to define the regulatory path.”
